Affordable Access

Recombinant interferon alpha-2b in the management of malignant pleural effusions.

Authors
  • Wilkins, H E 3rd
  • Connolly, M M
  • Grays, P
  • Marquez, G
  • Nelson, D
Type
Published Article
Journal
Chest
Publication Date
Jun 01, 1997
Volume
111
Issue
6
Pages
1597–1599
Identifiers
PMID: 9187180
Source
Medline
License
Unknown

Abstract

Twenty-one patients with malignant pleural effusion (MPE) were prospectively entered into a nonrandomized, single-armed study to evaluate the efficacy and safety of recombinant interferon (IFN) alpha-2b (INTRON A; Schering-Plough; Kenilworth, NJ) as an intrapleural palliative agent. From March 1989 through February 1993 (48 months), 21 patients were entered into the study. No symptomatic effusion recurred and no substantial side effects were associated with treatment. This suggests recombinant IFN alpha-2b represents a safe and effective intrapleural agent for the palliation of MPE.

Report this publication

Statistics

Seen <100 times